PA
ETON icon

Parallel Advisors’s Eton Pharmaceutcials ETON Stock Holding History

Parallel Advisors’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11K Hold
303
– – ﹤0.01% 2908
2026
Q1 		$7.48K Buy
+303
New +$5.3K ﹤0.01% 2882

Other funds holding ETON

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return

Parallel Advisors's ETON Position: Q2 2026 in Review

Parallel Advisors held its Eton Pharmaceutcials (ETON) position steady in Q2 2026 at 303 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #2908.

Parallel Advisors first reported a position in ETON in Q1 2026 and has held it in 2 quarters since. 164 funds tracked by Wall St. Rank hold ETON as of Q2 2026.

  • Parallel Advisors held 303 shares of Eton Pharmaceutcials worth $11K as of Q2 2026.
  • Parallel Advisors left its Eton Pharmaceutcials share count unchanged in Q2 2026.
  • Eton Pharmaceutcials made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2908 holding.
  • Parallel Advisors first reported a position in Eton Pharmaceutcials in Q1 2026 and has held it in 2 quarters since.
  • 164 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.